Blog

On September 17-18, 2026, members of the ANABIO R&D team attended the First Scientific Conference of the Institute of Medical Laboratory, Bach Mai Hospital, a major scientific event bringing together researchers, clinicians, professors, physicians, and laboratory medicine experts from across Vietnam.

The conference provided a platform for scientists and healthcare professionals to exchange recent research findings, discuss emerging laboratory technologies, and explore new approaches to improving the quality of medical testing and clinical diagnostics at Bach Mai Hospital and throughout Vietnam.

One of the scientific presentations at the conference was delivered by Assoc. Prof. Dr. Nguyen Thi Van Anh, representative of the ANABIO Spore Research Center, R&D and scientific advisor of LiveSpo Pharma, presented the study: “Evaluation of the Effects of Nasal-Spray Bacillus Probiotics on Immune Markers, Pathogen Load, and the Nasal Microbiota in Children with Acute Respiratory Tract Infections.”

The presentation attracted considerable interest from participants, particularly regarding the potential of LiveSpo Navax to modulate respiratory microbiota, reduce pathogen burden, and influence local immune responses in children with acute respiratory tract infections. The findings also contributed to broader discussions on the emerging role of probiotics in respiratory health and the importance of the respiratory microbiome in infectious diseases.

The conference featured a wide range of scientific studies covering microbiology, molecular diagnostics, immunology, toxicology, biochemistry, hematology, and laboratory quality management.

Among the notable presentations was:“Phenotype and Genotype of Carbapenem Resistance in Klebsiella pneumoniae and Pseudomonas aeruginosa Isolated from a Central Hospital in Vietnam,”

presented by the research team led by Assoc. Prof. Ph.D. Mr Bui Tien Sy, Director of the Laboratory Center, 108 Military Central Hospital.

Another key presentation focused on:

“Metagenomic Next-Generation Sequencing for Viral Detection in Influenza-Like Illness and Acute Respiratory Infection: Clinical Value, Challenges and Implementation Perspectives,”

presented by Ph.D. MD Truong Thai Phuong, Deputy Director of the Institute of Medical Laboratory and Head of the Department of Microbiology, Bach Mai Hospital.

The presentation highlighted the growing potential of metagenomic next-generation sequencing (mNGS) for detecting infectious agents, particularly in complex respiratory infections where conventional diagnostic methods may not identify the causative pathogen.

A major highlight of the final conference session was the handover of a next-generation sequencing (NGS) system to Bach Mai Hospital with the participation of the U.S. Embassy-Centers for Disease Control and Prevention, supporting the hospital’s capacity in molecular diagnostics and advanced biomedical research. The conference also included discussions involving organizations and experts working in laboratory quality assessment and quality assurance, emphasizing the increasing importance of standardized laboratory systems and internationally recognized quality frameworks.

For ANABIO R&D, the conference provided not only valuable scientific updates but also practical insights for strengthening research activities and laboratory quality management.

Following the conference, Assoc. Prof. Dr. Nguyen Thi Van Anh provided strategic direction for the R&D team to further standardize the Probiotic Spore Laboratory, strengthen quality management systems, improve research and testing procedures, and progressively move toward internationally recognized laboratory standards.

Participation in the conference represented an important opportunity for ANABIO to stay connected with advances in laboratory medicine, expand scientific collaboration with hospitals and research institutions, and continue developing applied research in probiotics, the human microbiome, and health sciences.

Vitafoods Asia 2026 took place from September 2–4, 2026, at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand.

Organized by Informa Markets, Vitafoods Asia 2026 covered approximately 30,000 m² and brought together more than 800 companies, representing an approximately 30% increase compared with the previous edition. Under the theme “Nutraceutical Trends Across Generations,” the exhibition focused on nutrition and healthcare solutions designed to address the needs of different age groups, from children and women to older adults. For ANABIO R&D, the event provided not only an opportunity to showcase Bacillus spore-based probiotic technologies researched and developed in Vietnam, but also a platform to explore emerging technologies, products, and scientific evidence in the global market.

1. Probiotics at Vitafoods Asia 2026: Diversifying Applications and Advancing Technology

Within the broader landscape of Vitafoods Asia 2026, probiotics and microbiome-modulating solutions continued to attract strong interest from both industry and the research community. The presence of the International Probiotics Association (IPA), together with ingredient manufacturers, microbial strain developers, and finished-product companies, reflected continued progress in translating microbiome research into health-related products.

Notably, a number of international probiotic companies presented products and technologies targeting increasingly specialized health needs, including Morinaga, SYNGEN Biotech, and Lallemand Health Solutions. This growing diversity also places greater demands on research and development.

One of the notable scientific sessions at Vitafoods Asia 2026 was presented by the International Probiotics Association (IPA), bringing together four experienced experts to discuss key challenges in probiotic product development, particularly the need to maintain product quality, scientific credibility, and consumer trust. A key message emerging from the discussion was that the value of a probiotic product lies not only in identifying promising microbial strains, but also in successfully translating research findings into products with consistent quality, robust scientific evidence, and transparent communication.

• LiveSpo: High-Concentration, Multi-Strain Spore-Based Probiotic Technology from Vietnam

Amid the diversity of probiotic solutions presented internationally, LiveSpo Pharma has been described as the world’s first and only manufacturer to successfully produce high-quality, multi-strain spore-based probiotics in liquid form, enabling the development of clinically evaluated products across a range of applications, according to PR Newswire. At Vitafoods Asia 2026, LiveSpo showcased probiotic products designed to address health needs ranging from digestive to respiratory health.

At booth H1-D50, LiveSpo showcased DIA30, CLAUSY, KIDS, PREGMOM, and NAVAX. Among these, DIA30 and CLAUSY are notable gastrointestinal probiotic products supported by clinical research. In clinical trials involving children with persistent diarrhea, both products demonstrated benefits as adjuncts to standard treatment, shortening recovery time by 3 days compared with the control groups. In the DIA30 study, the duration of antibiotic use was also reduced by approximately 25% compared with the control group. These findings highlight the potential role of probiotics as supportive interventions within strategies aimed at promoting the appropriate use of antibiotics.

Notably, LiveSpo® NAVAX represents one of LiveSpo’s pioneering innovations. In a NutraIngredients preview of exhibitors at Vitafoods Asia 2026, the product was featured as a nasal spray probiotic designed to support respiratory health.

NAVAX: A Probiotic Highlight for Respiratory Health at Vitafoods Asia 2026

While most conventional probiotic products are administered orally, LiveSpo NAVAX stands out as a nasal spray probiotic based on beneficial Bacillus spores, expanding the application of probiotics directly to the respiratory mucosa.

In a trial involving 400 children aged 2–5 years, 28 days of NAVAX use was associated with an incidence of new viral infections approximately one-sixth that of the control group, while the incidence of new bacterial infections was approximately half that observed in the control group. Changes in the nasal microbiota were also observed, including increased abundance of Bacillus and Brevibacillus (Pham et al., 2026).

Another clinical trial in children with RSV-associated pneumonia and bacterial coinfection found that NAVAX, when used alongside standard treatment, was associated with shorter times to symptom improvement and treatment completion (Le et al., 2025).

The combination of high-concentration probiotic spore technology, local administration, and a clinical research-driven development approach helped distinguish NAVAX within the LiveSpo product portfolio at Vitafoods Asia 2026.

Beyond the diversity of its product portfolio, LiveSpo also brought to the exhibition an overarching research vision: “A Future Without Antibiotics.” This message reflects the company’s commitment to developing scientifically supported probiotic solutions that can contribute, where appropriate, to prevention, healthcare, and treatment support, while promoting the rational use of antibiotics.

For ANABIO R&D, the technological trends, product innovations, and scientific evidence presented at Vitafoods Asia 2026 provide valuable references for future research and development. These insights also support the continued development of more specialized probiotic solutions with strong practical applicability and an increasingly robust scientific evidence base.

From August 11 to 14, members of the ANABIO R&D research team embarked on a meaningful trip to the coastal city of Quy Nhon to attend the 3rd International Conference on Microbiology and One Health (MOH-VN). The trip was not only an opportunity to share dedicated research results but also a wonderful journey for Anabio’s scientific team to network, learn, and gain new perspectives from the research community.

Held in the inspiring space of the International Centre for Interdisciplinary Science and Education (ICISE), this year’s MOH-VN conference brought together experts, PhDs, students, and individuals with a deep interest in microbiology. At the conference, the research team brought a thirst for learning and new knowledge, networking and exchanging expertise with the scientific community while also sharing the team’s clinical research stories with the broader expert community.

Assoc. Prof. Dr Nguyen Thi Van Anh presenting on the application of Bacillus spore probiotics in nasal spray form (Navax) at Plenary Session 1.

A highlight of the trip was Plenary Session 1 on August 11, when Assoc. Prof. Dr Nguyen Thi Van Anh presented report O-03. She shared positive research results on using Bacillus spore probiotics in nasal spray form (Navax). The study, which looked at reducing antibiotic use and improving symptoms in children with RSV, received close attention and helpful feedback from experts at the conference.

The next day afternoon, at the poster exhibition area, the research team had the opportunity to converse, exchange clinical trial design experiences, and share research data on supplementing with the Pregmom probiotic product to support digestive improvement in young children.

After the MOH-VN 2026 conference, the ANABIO R&D team returned with the proud “Best Poster Award” certificate and an abundance of positive energy. The knowledge gained from the conference will undoubtedly inspire members to continue new projects, stepping firmly together on the journey of bringing beneficial probiotics to care for community health.

Representatives of the ANABIO R&D research team are proudly receiving the “Best Poster Award” from the Organising Committee.